ACHC

IDEXX Laboratories, Inc. IDXX is set to release third-quarter 2026 results on Nov. 2, before the opening bell. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $4.27, which surpassed the Zacks Consensus Estimate by 8.10%. IDEXX's earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.74%. The Zacks Consensus Estimate for revenues is pegged at $1.19 billion, indicating an increase of 7.5% from the year-ago figure. The Zacks Consensus Estimate for EPS is pinned at $3.71, implying a rise of 9.1% from the year-ago figure. Estimates for third-quarter earnings have remained unchanged in the past 60 days. Here's a brief snapshot of the pet healthcare innovator's performance leading up to the announcement. The business is likely to have sustained its momentum in the third quarter of 2026, supported by continued volume growth. CAG Diagnostics' recurring revenues are expected to have been a key driver of this performance, with robust gains across both the U.S. and international regions. IDEXX VetLab consumables might have benefited from volume expansion driven by net new customer gains in the premium instrument installed base and expanded testing utilization. Global Reference Lab revenues are likely to have benefited from an expanding customer base and increased same-store utilization, as existing customers adopted a broader testing menu, such as IDEXX Cancer Dx. Global Rapid Assay revenues are expected to have improved as the impact of customers transitioning pancreatic lipase testing to the Catalyst instrument platform gradually subsides. Within Veterinary Software, Services and Diagnostic Imaging Systems, recurring revenue growth was likely supported by expanding cloud-based PIMS recurring revenues and increased adoption of the newly launched DR50 Plus platform. Additionally, the September acquisition of CoVetAI Inc. is expected to strengthen IDEXX's global software presence through integration with IDEXX VetConnect PLUS while addressing the needs of veterinary practice teams in markets not currently served by its practice management systems. On the flip side, continued pressure on wellness visits might have remained a key constraint on clinical visit growth during the third quarter. The Zacks Consensus Estimate for CAG's third-quarter business revenues implies an increase of 7.9%. The segment's revenues are expected to have benefited from both the United States and international regions, including benefits from order recovery in the Middle East. The Zacks Consensus Estimate for Water's revenues implies 6.4% year-over-year growth. IDEXX Laboratories, Inc. price-eps-surprise | IDEXX Laboratories, Inc. Quote Revenues in this division might have gained from an increase in test volumes across all regions. The Zacks Consensus Estimate for LPD revenues indicates a 3.5% year-over-year increase. Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is exactly the case here, as you can see below: Earnings ESP: IDEXX Laboratories has an Earnings ESP of +0.59%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Here are some other medical stocks worth considering, as these too have the right combination of elements to post an earnings beat this time around: TG Therapeutics TGTX has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon. TGTX's earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter's figure. Revvity RVTY has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3. RVTY's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter's figure. Acadia Healthcare ACHC has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4. ACHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter's figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report Revvity Inc. (RVTY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Align Technology, Inc. ALGN is set to release third-quarter 2026 results on Oct. 28, after the closing bell. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.64, which surpassed the Zacks Consensus Estimate by 3.13%. Align Technology beat on earnings in each of the trailing four quarters, the average surprise being 9.36%. The Zacks Consensus Estimate for revenues is pegged at $1.01 billion, which suggests 1.1% growth from the year-ago reported figure. The Zacks Consensus Estimate for earnings is pinned at $2.77 per share, which implies a 6.1% rise from the year-ago recorded actuals. Estimates for earnings have moved south 1 cent to $2.77 per share in the past 30 days. Here's a brief overview of the company's performance leading up to this announcement. The segment is likely to have benefited from higher Clear Aligner volumes, with particular strength across the EMEA, APAC and Latin America, with continued stability in North America. Both orthodontists and GP dentist channels may have seen volume growth, driven by growth across adults, teens and growing kids. From a product standpoint, it is likely to have seen strong contributions from Invisalign First, the Invisalign Palatal Expander and the Invisalign Mandibular Advancement with Occlusal Blocks ("MOAB"). Dental and orthodontic service organizations (DSOs) must have remained a key, scalable growth channel in the to-be-reported quarter, with continued strong progress across all major regions. Meanwhile, the doctor subscription program (DSP), which includes retention, touch-up and relapse cases, is expected to have maintained strong momentum during the quarter. The Zacks Consensus Estimate for Clear Aligner revenues indicates 3.6% year-over-year growth. Labcorp Holdings Inc. price-eps-surprise | Labcorp Holdings Inc. Quote Within this segment, revenues are likely to have faced a negative impact from continued challenges in the capital equipment market with higher interest rates and increased macro uncertainty. However, in the previous quarter, scanner placements to new doctors reached a record level and increased double digits year over year, driven by continued adoption of iTero Lumina. We expect this trend to have continued in the to-be-reported quarter as well. exocad achieved strong revenue growth, reinforcing the company's strategy to integrate orthodontics and restorative dentistry within a customer and patient-centric digital platform. We expect this trend to have persisted in the third quarter as well. The company introduced two new Align Digital Platform capabilities to enhance patient engagement, treatment planning and workflow efficiency. Combined with the Invisalign Palatal Expander platform and customized 3D-printed features, these innovations support a more integrated digital workflow from imaging and diagnosis to treatment delivery. We expect the development to have contributed to the company's top-line growth. The Zacks Consensus Estimate for the segment's revenues implies a decrease of 8% on a year-over-year basis. Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, this is not the case here, as you can see below: Earnings ESP: Align Technology has an Earnings ESP of -2.03%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank stocks here. Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around: TG Therapeutics TGTX has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon. TGTX's earnings beat estimates in one of the trailing four quarters and missed on the remaining three occasions, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter's figure. Revvity RVTY has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3. RVTY's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter's figure. Acadia Healthcare ACHC has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4. ACHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter's figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report Revvity Inc. (RVTY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Danaher Corporation DHR reported third-quarter 2026 adjusted earnings of $2.11 per share, beating the Zacks Consensus Estimate of $1.92 by 9.9%. The bottom line increased 11.6% year over year from $1.89 per share. Stronger profitability in the Biotechnology segment supported results. Revenues of $6.55 billion were in line with the consensus estimate of $6.55 billion and grew 8.5% year over year. Core sales rose 3.0%, while core sales excluding respiratory testing advanced 5.5%. Acquisitions contributed to reported growth, led by the Diagnostics segment. Revenues from the Biotechnology segment totaled $1.81 billion, up 0.5% year over year from $1.80 billion. Core sales rose 5.0%. Adjusted operating profit increased to $756 million from $669 million, while adjusted operating margin expanded 460 basis points to 41.8%. The segment's reported operating profit rose to $477 million from $352 million. Life Sciences revenues were $1.87 billion, up 4.0% from $1.79 billion in the prior-year quarter. Core sales increased 4.5%. Adjusted operating profit climbed to $404 million from $376 million, and adjusted operating margin improved 70 basis points to 21.7%. Reported operating profit increased to $259 million from $222 million. Diagnostics sales totaled $2.88 billion, increasing 17.0% from $2.46 billion a year earlier. Acquisitions contributed 16.5 percentage points to reported growth. Core sales edged up 0.5%, but core sales excluding respiratory testing increased 7.0%. Adjusted operating profit increased to $831 million from $728 million, although adjusted margin narrowed 80 basis points to 28.8%. The acquisition-led expansion in the Diagnostics segment contrasted with the relatively modest growth in underlying respiratory-related testing. Respiratory testing revenues were approximately $350 million compared with about $500 million in the year-ago period. The decline remained a headwind to overall core growth. At the company level, acquisitions and divestitures contributed 6.5% to reported sales growth. Danaher Corporation price-consensus-eps-surprise-chart | Danaher Corporation Quote Danaher's cost of sales rose 7.4% year over year to $2.72 billion. Gross profit increased 8.9% to $3.84 billion, with gross margin of 58.5% compared with 58.2% a year earlier. Selling, general and administrative expenses increased 8.4% to $2.16 billion. Research and development expenses rose 14.6% to $433 million. Operating profit increased 7.9% to $1.25 billion, while reported operating margin slipped to 19.0% from 19.1%. Adjusted operating profit rose to $1.90 billion from $1.69 billion, lifting adjusted operating margin to 29.0% from 27.9%. Exiting the third quarter, DHR had cash and equivalents of $5.68 billion compared with $4.62 billion at 2025-end. Long-term debt was $24.39 billion at the end of the quarter compared with $18.42 billion at the end of December 2025. Danaher generated net cash of $4.74 billion from operating activities in the first nine months of 2026 compared with $4.30 billion in the previous year's comparable period. Capital expenditures totaled $761 million in the same period, down 3.1% year over year. Free cash flow increased 13.0% year over year to $3.98 billion in the first nine months of 2026. In the same period, DHR paid out dividends of $790 million, up 21.2% on a year-over-year basis. For the fourth quarter of 2026, Danaher projects core revenue growth, excluding respiratory testing, of 4.0-5.0% year over year. Respiratory revenues are expected to create a headwind of roughly 150 basis points, resulting in anticipated overall core sales growth of approximately 3.0%. Adjusted operating margin is projected at about 29.5%. For full-year 2026, Danaher raised its adjusted earnings guidance to $8.57-$8.62 per share from the prior range of $8.45-$8.60. The company expects full-year core revenue growth of about 2.5%, with mid-single-digit growth excluding respiratory testing. Its Life Sciences business is forecast to deliver 3.0-4.0% core sales growth for the year. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Here are some other companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle. Acadia Healthcare Company, Inc. ACHC has an Earnings ESP of +4.84% and a Zacks Rank of 3 at present. The company is slated to release third-quarter 2026 results on Nov. 4. Acadia Healthcare's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 47%. Agios Pharmaceuticals, Inc. AGIO has an Earnings ESP of +9.37% and a Zacks Rank of 3 at present. The company is scheduled to release third-quarter 2026 results on Nov. 5. Agios Pharmaceuticals' earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 7.4%. Becton, Dickinson and Company BDX has an Earnings ESP of +0.21% and a Zacks Rank of 2 at present. The company is slated to release fourth-quarter fiscal 2026 (ended September 2026) results on Nov. 5. Becton's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 2.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Danaher Corporation (DHR) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Labcorp Holdings Inc. LH is slated to report its third-quarter 2026 results on Oct. 28, before the market opens. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $4.99, surpassing the Zacks Consensus Estimate by 4.18%. Labcorp outpaced estimates in each of the trailing four quarters, the average surprise being 3.09%. The Zacks Consensus Estimate for Labcorp's third-quarter 2026 revenues is pegged at $3.77 billion. This suggests a 5.7% rise from the year-ago reported figure. The Zacks Consensus Estimate for third-quarter EPS indicates an improvement of 11.2% to $4.65. The estimate has remained unchanged in the past 30 days. Here's a quick review of the company's performance leading up to its third-quarter earnings. In the third quarter of 2026, Diagnostics Laboratories ("Dx") segment's performance is likely to have benefited from continued organic growth, supported by strong testing volumes and increasing tests per accession. Labcorp is expected to have benefited from its ongoing expansion through health system partnerships and laboratory acquisitions, strengthening its patient and provider network and supporting testing demand. In the previous quarter, Labcorp's acquisition of select outreach laboratory services from Parkview Health in Indiana and Ohio, along with Tribal Diagnostics in Oklahoma and Texas, is expected to have supported third-quarter sales growth. Additionally, strategic collaborations with the National Association of Community Health Centers and OHSU's Knight Cancer Institute, along with an agreement with the Defense Health Agency to continue providing clinical reference laboratory services to the Military Health System, are expected to have strengthened Labcorp's market presence and growth prospects. The company's expanding specialty testing portfolio likely remained another tailwind. These tests are focused on the areas spanning oncology, women's health, neurology and autoimmune disease, which are projected to far outpace the broader diagnostics market. In the third quarter of 2026, Labcorp Oncology's performance is likely to have benefited from portfolio expansion across lung, colorectal and prostate cancer. This is supported by the nationwide launch of ColoSense, an RNA-based colorectal cancer screening test with an at-home collection, and the addition of advanced DPYD genotyping testing, which helps identify patients at risk for severe treatment-related toxicity from certain chemotherapies. Additionally, in August, the nationwide availability of Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay, which helps identify prostate cancer patients eligible for treatment with AstraZeneca's TRUQAP-based combination therapy, is expected to have further strengthened the company's oncology testing portfolio. In the third quarter of 2026, Labcorp OnDemand's revenues are expected to have benefited from strong demand for consumer health tests, supported by the expansion of its direct-to-consumer testing portfolio. The introduction of the Marker by Labcorp Genetic Health Panel, offering integrated biomarker and genetic testing insights, along with the launch of at-home self-collection tests for fertility-related hormones and testosterone levels in Canada, is likely to have further supported growth. Labcorp is also expected to have benefited from its continued adoption of advanced technologies, including AI and robotics, to enhance customer experiences and operational efficiency. The growing adoption of its recently launched AI-powered MyLabcorp app, which has already attracted millions of downloads, is likely to have further supported customer engagement and productivity. The Zacks Consensus Estimate expects Dx revenues to grow 6% year over year. Labcorp Holdings Inc. price-eps-surprise | Labcorp Holdings Inc. Quote Within the Biopharma Laboratory Services ("BLS") segment, Labcorp is likely to have benefited from the solid performance of Central Laboratories. The company may have also progressed with its strategic actions to streamline the Early Development business, which may have limited overall growth. During the third quarter, Labcorp acquired MLM Medical Labs ("MLM"), a leading global central and specialty laboratory provider. The acquisition strengthens Labcorp's global presence and biomarker testing capabilities, establishing a wholly owned laboratory network across North America, Europe, Asia and Africa. The Zacks Consensus Estimate suggests that BLS revenues will grow 3.9% year over year. Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below: LH's Earnings ESP: Labcorp has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Labcorp's Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here. Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time: TG Therapeutics TGTX has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon. TGTX's earnings beat estimates in one of the trailing four quarters and missed on the remaining three occasions, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter's figure. Revvity RVTY has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3. RVTY's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter's figure. Acadia Healthcare ACHC has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4. ACHC's earnings surpassed estimates in all of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter's figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Labcorp Holdings Inc. (LH) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report Revvity Inc. (RVTY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Danaher Corporation DHR is scheduled to release third-quarter 2026 results on Oct. 21, before market open. The Zacks Consensus Estimate for revenues is pegged at $26.3 billion, which indicates an increase of 8.2% from the year-ago quarter's figure. The consensus mark for earnings is pinned at $1.94 per share, which has remained steady in the past 30 days. The estimate indicates an increase of 1.6% from the figure reported in the year-ago quarter. The company's bottom line surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 5.7%. Let's see how things have shaped up for Danaher this earnings season. Strength in the bioprocessing business, driven by an increase in demand from large pharmaceutical and biopharma customers, is expected to have aided the Biotechnology segment. The segment's performance is also likely to have benefited from solid demand for equipment and consumables. For the third quarter, the Zacks Consensus Estimate for the segment's total sales is pegged at $1.87 billion, indicating a 3.9% rise from the year-ago reported number. Stabilizing pricing and improving volumes, as procurement and reimbursement effects have begun to moderate, are expected to drive the Diagnostics segment's results. For the third quarter, the Zacks Consensus Estimate for the segment's total sales is pegged at $2.83 billion, indicating a 15% rise from the year-ago reported number. Increase in demand across filtration, instruments and consumables businesses is likely to have boosted the performance of the Life Sciences segment in the quarter. For the third quarter, the Zacks Consensus Estimate for the segment's total sales is pegged at $1.84 billion, indicating a 2.8% rise from the year-ago reported number. Danaher acquired Masimo in June 2026, which expanded the Diagnostics segment by adding sensor technology and AI-enabled monitoring. This is expected to have augmented the company's top line in the third quarter. However, the escalating costs and operating expenses, due to increasing input costs and product mix changes, are likely to have weighed on DHR's bottom line in the to-be-reported quarter. The company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability. Danaher Corporation price-eps-surprise | Danaher Corporation Quote Our proven model predicts an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below. Earnings ESP: DHR has an Earnings ESP of +0.30% as the Most Accurate Estimate is pegged at $1.93 per share, which is higher than the Zacks Consensus Estimate of $1.92. You can uncover the best stocks before they're reported with our Earnings ESP Filter. Zacks Rank: DHR currently carries a Zacks Rank of 2. You can see the complete list of today's Zacks #1 Rank stocks here. Here are some other companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle. Acadia Healthcare Company, Inc. ACHC has an Earnings ESP of +4.84% and a Zacks Rank of 3 at present. The company is slated to release third-quarter 2025 results on Nov. 4. Acadia Healthcare's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 47%. Agios Pharmaceuticals, Inc. AGIO has an Earnings ESP of +9.37% and a Zacks Rank of 3 at present. The company is scheduled to release third-quarter 2026 results on Nov. 5. Agios Pharmaceuticals' earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 7.4%. CVS Health Corporation CVS has an Earnings ESP of +0.79% and a Zacks Rank of 3 at present. The company is slated to release third-quarter 2026 results on Nov. 4. CVS Health's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 20.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Danaher Corporation (DHR) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Elevance Health, Inc. ELV is set to report its third-quarter 2026 results on Oct. 21, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's earnings is currently pegged at $4.66 per shareon revenues of $48.60 billion. The third-quarter earnings estimate witnessed one downward revision and no upward revisions over the past 60 days. The bottom-line projection indicates a year-over-year decline of 22.7%. Also, the Zacks Consensus Estimate for quarterly revenues implies a year-over-year decrease of 3%. Image Source: Zacks Investment Research For 2026, the Zacks Consensus Estimate for Elevance's revenues is pegged at $195.4 billion, implying a decline of 1.1% year over year. The consensus mark for 2026 EPS is pegged at $27.22, indicating a 10.1% year-over-year decrease. Elevance's earnings beat the consensus estimate in each of the trailing four quarters, with the average surprise being 16.6%. This is depicted in the figure below. Elevance Health, Inc. price-eps-surprise | Elevance Health, Inc. Quote Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here. ELV currently has an Earnings ESP of 0.00% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. The Zacks Consensus Estimate for product revenues indicates 5.3% growth from the year-ago period's $6.16 billion. However, the consensus estimate for premiums indicates a 4.9% decrease from the year-ago period. The consensus mark for Commercial Individual membership implies a 17.3% fall from a year ago, while our model estimate indicates an 18.1% decline. Also, declining memberships in Medicaid (-6.8%) are likely to have kept third-quarter performance in check. However, the consensus estimate for Commercial Fee-based memberships indicates 1.7% year-over-year growth. Meanwhile, the Zacks Consensus Estimate for Carelon brand's operating income for the third quarter indicates a 0.2% year-over-year decrease. The consensus estimate for the Health Benefits segment's operating income for the third quarter indicates a 23.9% year-over-year plunge, making an earnings beat uncertain. The Zacks Consensus Estimate for the benefit expense ratio is pegged at 91.4, higher than the year-ago level of 91.3, which could further weigh on profitability during the quarter. Nevertheless, our model estimate for total expenses indicates a 5.5% year-over-year decline, which is likely to have provided some respite. While an earnings beat looks uncertain for Elevance, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around: Aveanna Healthcare Holdings Inc. AVAH has an Earnings ESP of +3.28% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Aveanna Healthcare's bottom line for the to-be-reported quarter of 20 cents indicates 33.3% year-over-year growth. It has witnessed one upward revision against no downward movement over the past 60 days. The consensus mark for revenues predicts a 9.9% increase from a year ago. CVS Health Corporation CVS has an Earnings ESP of +0.79% and a Zacks Rank of 3. The Zacks Consensus Estimate for CVS Health's bottom line for the to-be-reported quarter indicates a 1.3% increase from a year ago. The company's earnings beat estimates in each of the trailing four quarters, with an average surprise of 20.5%. The consensus estimate for CVS' revenues is pegged at $105.04 billion, signaling a 2.1% increase. Acadia Healthcare Company, Inc. ACHC has an Earnings ESP of +4.84% and a Zacks Rank of 3. The Zacks Consensus Estimate for Acadia Healthcare's bottom line for the to-be-reported quarter is pegged at 46 cents per share, which remained stable over the past week. Its earnings beat estimates in each of the past four quarters, with an average surprise of 47%. ACHC's revenues for the to-be-reported quarter are pegged at $869.26 million, a 2.1% increase from the year-ago period. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Elevance Health, Inc. (ELV) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report Aveanna Healthcare Holdings Inc. (AVAH) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Acadia Healthcare (ACHC). This company, which is in the Zacks Medical - Hospital industry, shows potential for another earnings beat. This provider of inpatient behavioral health care services has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 23.65%. For the last reported quarter, Acadia Healthcare came out with earnings of $0.38 per share versus the Zacks Consensus Estimate of $0.33 per share, representing a surprise of 15.15%. For the previous quarter, the company was expected to post earnings of $0.28 per share and it actually produced earnings of $0.37 per share, delivering a surprise of 32.14%. With this earnings history in mind, recent estimates have been moving higher for Acadia Healthcare. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Acadia Healthcare currently has an Earnings ESP of +4.84%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #2 (Buy) indicates that another beat is possibly around the corner. When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss. Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Acadia Healthcare trades at $28.83 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 17.5%. Is there a buying opportunity in Acadia Healthcare, or does it present a risk to your portfolio? See what our analysts have to say in our full research report, it's free. We're passing on Acadia Healthcare for now. Here are three reasons we avoid ACHC, plus one stock we'd rather own. Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful Hospital Chains company because there's a ceiling to what customers will pay. Acadia Healthcare's admissions came in at 54,141 in the latest quarter, and over the last two years, averaged 4.5% year-on-year growth. This performance slightly lagged the sector and suggests it might have to lower prices or invest in product improvements to accelerate growth, factors that can hinder near-term profitability. We track the long-term change in earnings per share (EPS) because it highlights whether a company's growth is profitable. Sadly for Acadia Healthcare, its EPS declined by 12.4% annually over the last five years while its revenue grew by 8.7%. This tells us the company became less profitable on a per-share basis as it expanded. A company's ROIC, or return on invested capital, shows how much operating profit it makes compared to the money it has raised (debt and equity). Unfortunately, Acadia Healthcare's ROIC has decreased significantly over the last few years. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between. Acadia Healthcare doesn't pass our quality test. That said, the stock currently trades at 17.1× forward P/E (or $28.83 per share). This valuation tells us a lot of optimism is priced in - we think there are better opportunities elsewhere. We'd suggest looking at the most entrenched endpoint security platform on the market. ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time. Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.

As the Q2 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the hospital chains industry, including Acadia Healthcare (NASDAQ:ACHC) and its peers. Hospital chains operate scale-driven businesses that rely on patient volumes, efficient operations, and favorable payer contracts to drive revenue and profitability. These organizations benefit from the essential nature of their services, which ensures consistent demand, particularly as populations age and chronic diseases become more prevalent. However, profitability can be pressured by rising labor costs, regulatory requirements, and the challenges of balancing care quality with cost efficiency. Dependence on government and private insurance reimbursements also introduces financial uncertainty. Looking ahead, hospital chains stand to benefit from tailwinds such as increasing healthcare utilization driven by an aging population that generally has higher incidents of disease. AI can also be a tailwind in areas such as predictive analytics for more personalized treatment and efficiency (intake, staffing, resourcing allocation). However, the sector faces potential headwinds such as labor shortages that could push up wages as well as substantial investments needs for digital infrastructure to support telehealth and electronic health records. Regulatory scrutiny, and reimbursement cuts are also looming topics that could further strain margins. The 4 hospital chains stocks we track reported a strong Q2. As a group, revenues beat analysts' consensus estimates by 2.3%. Luckily, hospital chains stocks have performed well with share prices up 12.3% on average since the latest earnings results. With a network of over 250 facilities serving patients in 38 states and Puerto Rico, Acadia Healthcare (NASDAQ:ACHC) operates facilities providing mental health and substance use disorder treatment services across the United States. Acadia Healthcare reported revenues of $865.8 million, flat year on year. This print exceeded analysts' expectations by 2%. Overall, it was a strong quarter for the company with a beat of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations. Acadia Healthcare delivered the slowest revenue growth of the whole group. Investor expectations, however, were likely higher than Wall Street's published projections, leaving some wishing for even better results (analysts' consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 12.8% since reporting and currently trades at $28.50. Is now the time to buy Acadia Healthcare? Access our full analysis of the earnings results here, it's free. With a network spanning nine states and serving primarily urban and suburban communities, Tenet Healthcare (NYSE:THC) operates a nationwide network of hospitals, ambulatory surgery centers, and outpatient facilities providing acute care and specialty healthcare services. Tenet Healthcare reported revenues of $5.63 billion, up 6.8% year on year, outperforming analysts' expectations by 3.9%. The business had an exceptional quarter with a beat of analysts' EPS estimates and a solid beat of analysts' full-year EPS guidance estimates. Tenet Healthcare achieved the biggest analyst estimate beat and highest full-year guidance raise in the group. The market seems happy with the results as the stock is up 28.9% since reporting. It currently trades at $256.45. Is now the time to buy Tenet Healthcare? Access our full analysis of the earnings results here, it's free. With a network spanning 39 states and three countries, Universal Health Services (NYSE:UHS) operates acute care hospitals and behavioral health facilities across the United States, United Kingdom, and Puerto Rico. Universal Health Services reported revenues of $4.64 billion, up 8.3% year on year, exceeding analysts' expectations by 1.1%. Still, it was a mixed quarter as it posted a miss of analysts' full-year EPS guidance estimates. Universal Health Services delivered the weakest performance against analyst estimates among its peers. Interestingly, the stock is up 17.2% since the results and currently trades at $186.79. Read our full analysis of Universal Health Services's results here. With roots dating back to 1968 and a network spanning 20 states, HCA Healthcare (NYSE:HCA) operates a network of 190 hospitals and 150+ outpatient facilities providing a full range of medical services across the US and England. HCA Healthcare reported revenues of $20.23 billion, up 8.7% year on year. This print beat analysts' expectations by 2.4%. Zooming out, it was a mixed quarter as it also logged a beat of analysts' EPS estimates but a slight miss of analysts' full-year EPS guidance estimates. HCA Healthcare achieved the fastest revenue growth but had the weakest full-year guidance update of the whole group. The stock is up 16.1% since reporting and currently trades at $437.11. Read our full, actionable report on HCA Healthcare here, it's free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market's biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market's primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market's dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

A month has gone by since the last earnings report for Acadia Healthcare (ACHC). Shares have added about 11.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Acadia Healthcare due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Acadia Healthcare Company, Inc. before we dive into how investors and analysts have reacted as of late. Acadia Healthcare Q2 Earnings Beat Estimates on Higher Admissions Acadia Healthcare reported adjusted second-quarter earnings of 38 cents per share, which beat the Zacks Consensus Estimate by 15.2%. However, the bottom line declined 54% year over year. Total revenues declined 0.4% year over year to $865.8 million. The top line surpassed the Zacks Consensus Estimate by 2.5%. The better-than-expected quarterly results reflected strong patient demand, as admissions increased and same-facility patient days improved. Residential Treatment Facilities also delivered double-digit revenue growth. However, lower revenue per patient day, a shorter average length of stay and higher operating expenses weighed on profitability. Acute Inpatient Psychiatric Facilities revenues totaled $494.6 million, which remained flat year over year but beat the Zacks Consensus Estimate by 4.3%. Specialty Treatment Facilities' revenues declined 8.4% year over year to $133.5 million. Comprehensive Treatment Facilities revenues amounted to $141.2 million, flat year over year. Residential Treatment Facilities revenues increased 11.6% to $96.5 million. Same-facility revenues of $856.4 million edged down 0.1% year over year but beat the Zacks Consensus Estimate by 3.6%. Patient days increased 0.8%, while revenue per patient day declined 0.8%. Admissions grew 6.4% year over year. The average length of stay decreased 5.3% year over year and missed the consensus estimate by 3.2%. Overall facility patient days remained flat year over year, while admissions increased 6.3%. Revenue per patient day declined 0.4% year over year, and the average length of stay decreased 5.9%. Total operating expenses increased 7.3% year over year to $727.6 million, primarily due to higher salaries, wages and benefits, professional fees, supplies and other operating expenses. Total adjusted EBITDA declined 26% year over year to $149.2 million. During the quarter, the company added 240 licensed beds from newly constructed facilities. Acadia Healthcare exited the second quarter with cash and cash equivalents of $171.3 million, which increased from the 2025-end level of $133.2 million. It had remaining borrowing capacity of $669.8 million under its $1 billion revolving credit facility at the end of the second quarter. Total assets of $5.5 billion increased 0.3% from the 2025-end figure. Long-term debt amounted to $2.4 billion, which declined from $2.5 billion as of Dec. 31, 2025. The current portion of long-term debt was $32.5 million. Total equity of $2 billion increased from the 2025-end level of $1.9 billion. Net cash provided by operating activities totaled $223.6 million in the first six months of 2026 compared with $145.0 million in the prior-year period. The company did not buy back shares in the second quarter of 2026. Acadia Healthcare updated its 2026 guidance. The company now expects revenues to be in the range of $3.40-$3.45 billion compared with the previous guidance of $3.37-$3.45 billion. Adjusted EBITDA is now projected to be in the band of $590-$615 million compared with the previous outlook of $580-$615 million. Adjusted EPS is now expected to be $1.45-$1.60 compared with the earlier guidance of $1.35-$1.60. Management also raised its operating cash flow forecast to $350-$400 million from $285-$325 million. Capital expenditures are now expected to be $235-$255 million, down from the prior guidance of $255-$280 million. Management previously guided for the addition of 400-600 licensed beds in 2026. It turns out, fresh estimates have trended downward during the past month. The consensus estimate has shifted -7.71% due to these changes. Currently, Acadia Healthcare has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of C on the value side, putting it in the middle 20% for value investors. Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Acadia Healthcare has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Acadia Healthcare belongs to the Zacks Medical - Hospital industry. Another stock from the same industry, Community Health Systems (CYH), has gained 7.8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026. Community Health Systems reported revenues of $2.83 billion in the last reported quarter, representing a year-over-year change of -9.8%. EPS of -$0.19 for the same period compares with -$0.05 a year ago. Community Health Systems is expected to post a loss of $0.22 per share for the current quarter, representing a year-over-year change of -117.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -116.7%. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Community Health Systems. Also, the stock has a VGM Score of D. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report Community Health Systems, Inc. (CYH) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

In the past week, Acadia Healthcare Company, Inc. reported second-quarter 2026 results showing US$865.84 million in sales and a decline in net income to US$10.93 million, while also slightly lifting full-year 2026 revenue guidance to a range of US$3.40 billion to US$3.45 billion. Despite flat year-on-year quarterly revenue and higher liability reserves, the company beat consensus earnings forecasts, generated strong free cash flow, and raised its full-year adjusted EPS outlook, supported by new facility openings and disciplined financial management. We’ll now examine how Acadia’s upgraded full-year revenue and earnings guidance influences its existing investment narrative and risk profile. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource. To own Acadia, you need to believe that long term demand for behavioral health services and new facility growth can ultimately outweigh current profitability and reimbursement pressures. The latest quarter supports that narrative only modestly: revenue was flat and net income fell, but stronger free cash flow, reduced debt, and slightly higher 2026 guidance suggest the near term catalyst remains execution on new beds, while the biggest risk continues to be pressure from Medicaid reimbursement and liability and legal costs. The most relevant update here is Acadia’s decision to raise 2026 revenue guidance to US$3.40 billion to US$3.45 billion after reporting Q2 sales of US$865.84 million. That move, alongside a higher full year adjusted EPS outlook, ties directly into the key catalyst that many investors are watching: whether newly opened facilities and bed additions can contribute enough to offset Medicaid headwinds, start up losses, and underperforming locations without eroding margins. Yet beneath the higher guidance, investors should still be aware of rising liability reserves and ongoing legal and regulatory risks that could... Read the full narrative on Acadia Healthcare Company (it's free!) Acadia Healthcare Company's narrative projects $3.9 billion revenue and $189.9 million earnings by 2029. This requires 4.9% yearly revenue growth and an earnings increase of about $1.3 billion from -$1.1 billion today. Uncover how Acadia Healthcare Company's forecasts yield a $32.21 fair value, a 18% upside to its current price. Some of the most optimistic analysts were already assuming revenues near US$4.0 billion and earnings above US$260 million by 2029, which is a much rosier view than the baseline narrative. This new quarter and guidance raise may either support that faster ramp thesis or force a rethink on risks like start up losses and Medicaid pressure, so it is worth comparing these different expectations before deciding which story you find more convincing. Explore 4 other fair value estimates on Acadia Healthcare Company - why the stock might be worth over 3x more than the current price! Don't just follow the ticker - dig into the data and build a conviction that's truly your own. A great starting point for your Acadia Healthcare Company research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Our free Acadia Healthcare Company research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Acadia Healthcare Company's overall financial health at a glance. Our top stock finds are flying under the radar-for now. Get in early: Find 49 companies with promising cash flow potential yet trading below their fair value. Uncover the next big thing with 20 elite penny stocks that balance risk and reward. Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ACHC. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]